AIM
VKTX icon

Acrospire Investment Management’s Viking Therapeutics VKTX Stock Holding History

Acrospire Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,642
Closed -$18K – 2558
2017
Q1 		$18K Buy
12,642
+1,876
+17% +$2.62K 0.01% 1674
2016
Q4 		$13K Buy
10,766
+7,066
+191% +$7.97K 0.01% 1909
2016
Q3 		$5K Buy
3,700
+1,400
+61% +$1.85K ﹤0.01% 1827
2016
Q2 		$3K Buy
+2,300
New +$3.03K ﹤0.01% 1923

Other funds holding VKTX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Acrospire Investment Management's VKTX Position: Q2 2017 in Review

Acrospire Investment Management sold out of Viking Therapeutics (VKTX) in Q2 2017, closing a stake of 12,642 shares — an estimated $18K sold.

Acrospire Investment Management first reported a position in VKTX in Q2 2016 and held it in 4 quarters. The position peaked at $18K in Q1 2017. 12 funds tracked by Wall St. Rank hold VKTX as of Q2 2017.

  • Acrospire Investment Management reported no remaining Viking Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 12,642 Viking Therapeutics shares in Q2 2017, an estimated $18K.
  • Acrospire Investment Management first reported a position in Viking Therapeutics in Q2 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Viking Therapeutics position peaked at $18K in Q1 2017.
  • 12 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.